Durable remissions achieved with reinfusion of CD19‐directed CAR‐T despite failure to induce or maintain B‐cell aplasia and single‐center experience with reinfusion of tisagenlecleucel
Pediatric Blood & Cancer · 2023
DOI: 10.1002/pbc.30271 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pediatric Blood & Cancer, 2023. Verfasst von Thomas J Galletta und 7 weiteren Autor:innen. Beteiligte Einrichtung: Cincinnati Children's Hospital Medical Center Cancer and Blood Diseases Institute, Cincinnati, Ohio, USA. Hauptthemen laut MEDLINE: Receptors, Chimeric Antigen, Precursor Cell Lymphoblastic Leukemia-Lymphoma. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 28 Literaturangaben.
Abstract (Originalsprache)
CD19‐directed chimeric antigen receptor T lymphocytes (CAR‐T) have led to durable remissions in children with refractory and/or multiply relapsed B‐lymphoblastic leukemia. For those who relapse or lose B‐cell aplasia post CAR‐T, the role of CAR‐T reinfusion is unclear. We report two cases of durable remission with tisagenlecleucel reinfusion despite failure to achieve or maintain B‐cell aplasia, and compare these cases to six additional children who received multiple tisagenlecleucel infusions at our institution. Our experience suggests that reinfusion is safe and may be a definitive therapy for a small subset of patients. Reinfusion can also reintroduce remission and/or B‐cell aplasia, allowing for subsequent therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cincinnati Children's Hospital Medical Center Cancer and Blood Diseases Institute, Cincinnati, Ohio, USA.
- Cincinnati Children's Hospital Medical Center Division of Oncology, Cincinnati, Ohio, USA.
- University of Cincinnati College of Medicine Department of Pediatrics, Cincinnati, Ohio, USA.
- Cincinnati Children's Hospital Medical Center Division of Bone Marrow Transplantation and Immune Deficiency, Cincinnati, Ohio, USA.
ORCID-Profile: Thomas J Galletta, Jeremy D Rubinstein, Christopher E Dandoy, Stella M Davies
Zitieren
APA
Galletta, T. J., Rubinstein, J. D., Krupski, C., Nelson, A. S., Khoury, R., Dandoy, C. E., Davies, S. M., & Phillips, C. L. (2023). Durable remissions achieved with reinfusion of CD19‐directed CAR‐T despite failure to induce or maintain B‐cell aplasia and single‐center experience with reinfusion of tisagenlecleucel. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.30271
Vancouver
Galletta TJ, Rubinstein JD, Krupski C, Nelson AS, Khoury R, Dandoy CE, et al. Durable remissions achieved with reinfusion of CD19‐directed CAR‐T despite failure to induce or maintain B‐cell aplasia and single‐center experience with reinfusion of tisagenlecleucel. Pediatric Blood & Cancer. 2023. doi:10.1002/pbc.30271
BibTeX
@article{Galletta2023,
author = {Galletta, Thomas J and Rubinstein, Jeremy D and Krupski, Christa and Nelson, Adam S and Khoury, Ruby and Dandoy, Christopher E and Davies, Stella M and Phillips, Christine L},
title = {Durable remissions achieved with reinfusion of CD19‐directed CAR‐T despite failure to induce or maintain B‐cell aplasia and single‐center experience with reinfusion of tisagenlecleucel},
journal = {Pediatric Blood & Cancer},
year = {2023},
doi = {10.1002/pbc.30271}
}
EUVIMED